Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVM NYSE:IKT NYSE:PLX NYSE:RCOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$10.43+12.0%$6.28$1.98▼$39.30$71.78M0.52373,970 shs514,864 shsIKTInhibikase Therapeutics$1.80-2.2%$1.78$1.12▼$4.20$134.13M0.9188,350 shs71,026 shsPLXProtalix BioTherapeutics$1.55$1.51$0.90▼$3.10$123.59M-0.21830,486 shs672,081 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI+12.03%+9.56%+21.56%+396.67%-67.96%IKTInhibikase Therapeutics-2.17%-4.76%+9.09%-11.33%+29.50%PLXProtalix BioTherapeutics0.00%-6.63%+4.03%0.00%+72.22%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVMCEL-SCI0.5055 of 5 stars0.04.00.00.00.01.70.6IKTInhibikase Therapeutics2.0278 of 5 stars3.32.00.00.03.70.00.6PLXProtalix BioTherapeutics2.9747 of 5 stars3.52.00.00.02.11.71.9RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50261.11% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00867.74% UpsideRCORRenovacor 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APLXProtalix BioTherapeutics$61.95M1.99$0.09 per share17.80$0.47 per share3.30RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APLXProtalix BioTherapeutics$8.31M$0.07N/A5.00N/A-21.03%-30.89%-11.74%N/ARCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09IKTInhibikase TherapeuticsN/A0.850.85PLXProtalix BioTherapeuticsN/A1.981.27RCORRenovacorN/A6.606.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%IKTInhibikase Therapeutics3.81%PLXProtalix BioTherapeutics16.53%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%IKTInhibikase Therapeutics7.30%PLXProtalix BioTherapeutics6.50%RCORRenovacor14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI436.88 million64.67 millionOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableRCOR, IKT, PLX, and CVM HeadlinesRecent News About These CompaniesRenovacor, Inc. Common Stock (RCOR)June 12, 2025 | nasdaq.comBest budget record players 2024: affordable turntables tried and testedNovember 6, 2024 | whathifi.comWThe Lititz Record-ExpressOctober 25, 2024 | lancasteronline.comLWNBA Delivers Record-Setting 2024 SeasonOctober 13, 2024 | wnba.comWRBC Core Bond Pool ETF (RCOR)July 27, 2024 | investing.comRecord Store Day 2024: How to Flatten Warped Vinyl Records at HomeApril 22, 2024 | cnet.comThe best record players 2024: Top turntables for any budgetApril 20, 2024 | tomsguide.comTBest turntables 2024: Bluetooth record players for Record Store DayApril 20, 2024 | stuff.tvSNews of RecordMarch 30, 2024 | newsandsentinel.comNNHL opening night delivers record viewership on ESPNNovember 6, 2023 | nhl.comNState Pension payments worth over £2,000 each month for older people living in these European countriesOctober 30, 2023 | dailyrecord.co.ukDThe best early Black Friday turntable deals 2023October 28, 2023 | whathifi.comWAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisOctober 27, 2023 | dailyrecord.co.ukDNYC shoplifting hit record highs last year: ‘We can’t stop them’October 24, 2023 | nypost.comNTranscriptional control of the inflammatory responseOctober 18, 2023 | nature.comNRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of DirectorsOctober 17, 2023 | finance.yahoo.comFolwell criticizes fellow Republicans on public records rollbackOctober 14, 2023 | wral.comWBest Bluetooth turntables 2023: wireless record players for streaming vinylOctober 11, 2023 | whathifi.comWHere’s why you shouldn’t record meltdowns on an airplane: FAA insiderOctober 3, 2023 | nypost.comNRecord-breaking heat wave peaking in Eastern U.S. with highs near 100September 28, 2023 | washingtonpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCOR, IKT, PLX, and CVM Company DescriptionsCEL-SCI NYSE:CVM$10.43 +1.12 (+12.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.46 +0.03 (+0.25%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Inhibikase Therapeutics NYSE:IKT$1.80 -0.04 (-2.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protalix BioTherapeutics NYSE:PLX$1.55 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.58 +0.02 (+1.61%) As of 08/29/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
